Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 1

Conditions

Recurrence 1Glioma 1Extensive Stage Lung Small Cell Carcinoma 1

Interventions

pembrolizumab 1254Specimen Handling 869Carboplatin 818Magnetic Resonance Spectroscopy 804Cyclophosphamide 795Cisplatin 716Nivolumab 648Paclitaxel 623Radiotherapy 567Gemcitabine 565Biopsy 529Bevacizumab 468Dexamethasone 434fludarabine 404Docetaxel 373venetoclax 366Oxaliplatin 362Capecitabine 353Fluorouracil 352atezolizumab 341Rituximab 327durvalumab 326Doxorubicin 313Radiosurgery 306Pemetrexed 303Drug Therapy 295Standard of Care 292Ipilimumab 290Etoposide 280Radiation 278

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Lamivudine × 1 year × Clear all
NCT06494579 2025-12-16

Lamivudine for Solid Tumors

Icahn School of Medicine at Mount Sinai

Phase 1/2 Active not recruiting
12 enrolled

Recurrence

NCT04696575 2025-12-15

Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer

Roswell Park Cancer Institute

Phase 2 Recruiting
28 enrolled

Extensive Stage Lung Small Cell Carcinoma

NCT06428045 2025-06-22

STARLITE

University of Miami

Phase 1 Recruiting
24 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡